Now Playing
|Videos|August 18, 2022
Patient Profile 1: A Patient With HER2+ Metastatic BC Treated With T-DXd who Develops ILD
After reviewing the historical use of ADCs, panelists discuss the first patient profile of HER2+ metastatic breast cancer managed with trastuzumab deruxtecan.
Advertisement
Episodes in this series
Advertisement
Related to this article
A nurse-led support program significantly reduces death anxiety in women with breast cancer on hormonal therapy, study finds.
FDA approves imlunestrant plus abemaciclib for ESR1-mutated, ER-positive, HER2-negative advanced or metastatic breast cancer after endocrine therapy.
Patients often use AI to read test results, but AI can misinterpret data and cause panic. Learn why human context remains critical.
Oncology nursing teams must navigate the clinical logistics and patient education for the newly approved, ctDNA-guided agent camizestrant.
Oncology navigator Emily Beard shares insights on advocacy, the Young Survival Coalition, and dancing to sustain her career.
FDA approves camizestrant for ESR1-mutated advanced breast cancer, tasking oncology nurses with guiding patients through ctDNA-based surveillance.
Oncology clinicians must actively champion NCCN guidelines as a critical pillar of breast cancer survivorship care,
FDA grants accelerated approval to camizestrant with a CDK4/6 inhibitor for adult patients with ESR1-mutated HR+/HER2- advanced breast cancer.
Advertisement
Advertisement
Trending on Oncology Nursing News
1
FDA Approves Lirafugratinib for Advanced FGFR2+ Cholangiocarcinoma
2
How On-Body Treatment Delivery Reduces Nursing Burden in Myeloma Care
3
Nurse-Led Support Reduces Death Anxiety in Breast Cancer Care
4
Psycho-Oncology Care: Dr. Erik Bengtsen on Psilocybin & Patient Distress
5